Targeting topoisomerase I to inhibit hypoxia inducible factor 1

Cell Cycle

Volumn 3, Issue 2, 2004, Pages 172-175

  Rapisarda, Annamaria ^a   Shoemaker, Robert H ^b   Melillo, Giovanni ^a,b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer therapeutics; HIF 1; Hypoxia; Molecular targets; Topoisomerase I

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TOPOTECAN; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; DNA BINDING PROTEIN; HELIX LOOP HELIX PROTEIN; HIF1A PROTEIN, HUMAN; ISOENZYME; MEMBRANE PROTEIN; NUCLEAR PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; DNA DEGRADATION; GENETIC TRANSCRIPTION; HUMAN; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION; CELL CULTURE; CELL HYPOXIA; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CYCLOOXYGENASE 2; DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HELIX-LOOP-HELIX MOTIFS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOENZYMES; MEMBRANE PROTEINS; NUCLEAR PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SIGNAL TRANSDUCTION; TOPOTECAN; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3843078830     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92:5510-4.
2. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
3. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs, WB, Semenza GL, Simons JW. Overexpcession of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59:5830-5.
4. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der, WE. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93:309-14.
5. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris, AL. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor- associated, macrophages. Am J Pathol 2000; 157:411-21.
6. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, Harris AL. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/ molecular profile of tumours and survival. Br J Cancer 2001; 85:881-90.
7. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61:2911-6.
8. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60:4693-6.
9. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 2002; 62:2493-7.
10. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC, Harris AL. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 53:1192-202.
11. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7:1661-8.
12. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rossler K, Prodinger A, Budka H, Hainfellner JA. Expression of hypoxia-inducible factor-1 alpha oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001; 92:165-71.
13. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001; 61:1830-2.
14. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94:8104-9.
15. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required, for solid tumor formation and embryonic vascularization. EMBO J 1998; 17:3005-15.
16. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E, Keshet E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394:485-90.
17. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000; 60:4010-5.
18. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, Wang J, Shindo M, Higashino F, Takeda K, Asaka M, Katoh H, Sugiyama T, Hosokawa M, Kobayashi M. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003; 162:1283-91.
19. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000; 6:1335-40.
20. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14:34-44.
21. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M, Asaka M. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001; 61:6548-54.
22. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003; 4:133-46.
23. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 2001; 8:638-45.
24. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14:391-6.
25. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22:7004-14.
26. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60:1541-5.
27. Berra E, Pages G, and Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 2000; 19:139-45.
28. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, Gutkind JS. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000; 60:4873-80.
29. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002; 62:2478-82.
30. Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo H. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn J Cancer Res 2001; 92:1342-51.
31. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The Thioredoxin Redox Inhibitors 1-Methylpropyl 2-Imidazolyl Disulfide and Pleurotin Inhibit Hypoxia-induced Factor 1alpha and Vascular Endothelial Growth Factor Formation. Mol Cancer Ther 2003; 2:235-43.
32. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3:363-75.
33. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcript tonal activation pathway. Cancer Res 2002; 62:4316-24.
34. Larsen AK, Gobert C. DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde? Pathol Oncol Res 1999; 5:171-8.
35. Kohn KW, Shao RG, Pommier Y. How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair? Cell Biochem Biophys 2000; 33:175-80.
36. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker R, Melillo G. Topoisomerase I mediated inhibition of Hypoxia Inducible Factor-1 (HIF-1): mechanism and therapeutic implications. Cancer Res 2003; in press.
37. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP. Mechanism of action of camptothecin. Ann NY Acad Sci 2000; 922:1-10.
38. Fields AL, Runowicz CD. Current therapies in ovarian cancer. Cancer Invest 2003; 21:148-56.
39. Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Cancer 2003; 97:2498-503.
40. Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol 2003; 30:9-25.
41. Guarino MJ, Schneider CJ, Grubbs SS, Biggs DD, Himelstein AL, Hogaboom K, Tilak S. A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer. Oncologist 2002; 7:509-15.
42. Rose PG. Combined-modality therapy of locally advanced cervical cancer. J Clin Oncol 2003; 21:211-7.
43. Grabenbauer GG, Anders K, Fietkau RJ, Klautke G, Feldmann HJ, Weiser S, Staab HJ, Krauseneck P, Sauer R. Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma-a phase I study. J Neurooncol 2002; 60:269-75.
44. Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, Maksymiuk A, Hoskins P, Matthews S, Eisenhauer E. Phase II study of sequential topotecan and etopostde in patients with intermediate grade non-Hodgkins lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Leuk Lymphoma 2002; 43:1581-7.
45. Langler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study. Klin Padiatr 2002; 214:153-6.
46. Clements MK, Jones CB, Cumming M, Daoud SS. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol. 1999; 44:411-6.
47. O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999; 5:181-7.
48. Soffer SZ, Kim E, Moore JT, Huang J, Yokoi A, Manley C, O'toole K, Middlesworth W, Stolar C, Yamashiro D, Kandel J. Novel use of an established agent: Topotecan is antiangiogenic in experimental Wilms tumor. J Pediatr Surg 2001; 36:1781-4.
49. Kim ES, Soffer SZ, Huang J, McCrudden KW, Yokoi A, Manley CA, Middlesworth W, Kandel JJ, Yamashiro DJ. Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. J Pediatr Surg 2002; 37:518-22.
50. McCrudden KW, Yokoi A, Thosani A, Suffer SZ, Kim ES, Huang J, Manley C, O'toole K, Yamashiro DJ, Kandel JJ, Middlesworth W. Topotecan is anti-angiogenic in experimental hepatoblastoma. J Pediatr Surg. 2002; 37:857-61.
51. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-86.